Vanesa Quiroga

1.0k total citations
39 papers, 316 citations indexed

About

Vanesa Quiroga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vanesa Quiroga has authored 39 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Vanesa Quiroga's work include HER2/EGFR in Cancer Research (17 papers), Advanced Breast Cancer Therapies (14 papers) and Breast Cancer Treatment Studies (11 papers). Vanesa Quiroga is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Advanced Breast Cancer Therapies (14 papers) and Breast Cancer Treatment Studies (11 papers). Vanesa Quiroga collaborates with scholars based in Spain, United States and Germany. Vanesa Quiroga's co-authors include Rafael Rosell, Miquel Tarón, L. Ibarz, M. Mora, Dolors Rodríguez-Pardo, Juan José Sánchez, Albert Font, Cristina Carrato, P. Céliz and Ana Giménez‐Capitán and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Vanesa Quiroga

32 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vanesa Quiroga Spain	8	185	155	88	85	74	39	316
Nieves Martínez Chanzá Belgium	11	207 1.1×	109 0.7×	126 1.4×	38 0.4×	60 0.8×	32	329
A. D. Seidman United States	12	270 1.5×	99 0.6×	132 1.5×	92 1.1×	62 0.8×	37	413
Zubaida Fida Hussain Pakistan	12	154 0.8×	74 0.5×	79 0.9×	59 0.7×	89 1.2×	19	337
Xin-Ke Zhang China	7	215 1.2×	118 0.8×	67 0.8×	57 0.7×	65 0.9×	9	359
Shen Pan China	9	99 0.5×	140 0.9×	70 0.8×	102 1.2×	171 2.3×	14	335
Damian J. Ralser Germany	11	110 0.6×	73 0.5×	67 0.8×	59 0.7×	132 1.8×	35	325
Yu Ishizuya Japan	13	117 0.6×	150 1.0×	104 1.2×	154 1.8×	173 2.3×	36	402
Zuyi Yang China	10	119 0.6×	167 1.1×	38 0.4×	125 1.5×	184 2.5×	20	350
John Joseph Wright United States	8	141 0.8×	81 0.5×	80 0.9×	29 0.3×	72 1.0×	31	312

Countries citing papers authored by Vanesa Quiroga

Since Specialization

Citations

This map shows the geographic impact of Vanesa Quiroga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanesa Quiroga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanesa Quiroga more than expected).

Fields of papers citing papers by Vanesa Quiroga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanesa Quiroga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanesa Quiroga. The network helps show where Vanesa Quiroga may publish in the future.

Co-authorship network of co-authors of Vanesa Quiroga

This figure shows the co-authorship network connecting the top 25 collaborators of Vanesa Quiroga. A scholar is included among the top collaborators of Vanesa Quiroga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanesa Quiroga. Vanesa Quiroga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elorriaga, Kepa, Luis Álvarez, Vanesa Quiroga, et al.. (2025). Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response. Translational Oncology. 57. 102407–102407.

Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.

Hernandez, Laura L., Aintzane Urbizu, Paula Rodríguez‐Martínez, et al.. (2025). Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Modern Pathology. 38(9). 100787–100787.

Guerrero‐Zotano, Ángel, Manuel Ruíz‐Borrego, Begoña Bermejo, et al.. (2024). Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study. ESMO Open. 9(10). 103733–103733. 1 indexed citations

Hernandez, Laura L., Aintzane Urbizu, Paula Rodríguez‐Martínez, et al.. (2023). Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer. Cancers. 15(12). 3068–3068. 6 indexed citations

Rubió‐Casadevall, Jordi, Beatriz Cirauqui, Javier Martínez‐Trufero, et al.. (2023). TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Frontiers in Oncology. 13. 1226939–1226939. 7 indexed citations

Rubió‐Casadevall, Jordi, Alicia Lozano, María Buxó, et al.. (2023). Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population. Clinical & Translational Oncology. 25(8). 2384–2392. 1 indexed citations

Ussene, Esperança, Ana F. Castillo, Paula Rodríguez‐Martínez, et al.. (2022). Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. Scientific Reports. 12(1). 8176–8176. 6 indexed citations

Hurvitz, Sara A., Y.H. Park, Aditya Bardia, et al.. (2021). LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. Annals of Oncology. 32. S1285–S1286. 13 indexed citations

10.

Cirauqui, Beatriz, Teresa Morán, Anna Estival, et al.. (2020). Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology. 13(1). 130–138. 2 indexed citations

11.

Ciruelos, Eva, Álvaro Montaño, César A. Rodríguez, et al.. (2020). Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). European Journal of Cancer Care. 29(4). e13253–e13253. 7 indexed citations

12.

Oliveira, Mafalda, Patricia Villagrasa, Eva Ciruelos, et al.. (2020). 351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER). Annals of Oncology. 31. S389–S389. 1 indexed citations

13.

Felip, Eudald, Clara Pérez‐Mañá, Mireia Margelí Vila, et al.. (2019). New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib – A Case Report. Breast Care. 15(5). 548–552. 6 indexed citations

14.

Morán, Teresa, Vanesa Quiroga, Beatriz Cirauqui, et al.. (2019). A Single-Center Retrospective Study of Patients with Double Primary Cancers: Breast Cancer and <b><i>EGFR</i></b>-Mutant Non-Small Cell Lung Cancer. Oncology Research and Treatment. 42(3). 107–114. 6 indexed citations

15.

Quiroga, Vanesa, Beatriz Cirauqui, Margarita Romeo, et al.. (2019). Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients. Scientific Reports. 9(1). 12760–12760. 19 indexed citations

16.

Lucente, Giuseppe, Laura Vidal, Enric Carcereny, et al.. (2019). Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab. Clinical & Translational Oncology. 22(3). 411–419.

17.

Plaja, Andrea, et al.. (2018). Thromboembolism and bleeding in patients with cancer and mechanical heart valves. Journal of Thrombosis and Thrombolysis. 47(3). 454–461. 2 indexed citations

18.

Romeo, Margarita, Anna Martínez‐Cardús, Eva Martinez‐Balibrea, et al.. (2018). Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences. 19(10). 3249–3249. 5 indexed citations

19.

Quiroga, Vanesa, Esther Holgado, José Luis Alonso-Romero, et al.. (2018). Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Annals of Oncology. 29. x32–x32. 1 indexed citations

20.

Serra, Pere, José Sanz‐Santos, E. Castellà, et al.. (2017). Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound‐guided transbronchial needle aspiration. Cytopathology. 29(1). 35–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact